Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
Aducanumab
Alzheimer’s dementia
Alzheimer’s disease
Amyloid plaques
Disease-modifying therapy
Economic model
Institutionalization
Markov model
Natural history
Progression
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
23
06
2021
accepted:
05
08
2021
pubmed:
25
8
2021
medline:
25
8
2021
entrez:
24
8
2021
Statut:
ppublish
Résumé
Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease that places a substantial burden on patients and caregivers. Aducanumab is the first AD therapy approved by the US Food and Drug Administration to reduce a defining pathophysiological feature of the disease, brain amyloid plaques. In the phase 3 clinical trial EMERGE (NCT02484547), aducanumab reduced clinical decline in patients with mild cognitive impairment (MCI) due to AD and mild AD dementia and confirmed amyloid pathology. We used a Markov modeling approach to predict the long-term clinical benefits of aducanumab for patients with early AD based on EMERGE efficacy data. In the model, patients could transition between AD severity levels (MCI due to AD; mild, moderate, and severe AD dementia) and care settings (community vs. institution) or transition to death. The intervention was aducanumab added to standard of care (SOC), and the comparator was SOC alone. Data sources for base-case and scenario analyses included EMERGE, published National Alzheimer's Coordinating Center analyses, and other published literature. Per patient over a lifetime horizon, aducanumab treatment corresponded to 0.65 incremental patient quality-adjusted life-years (QALYs) and 0.09 fewer caregiver QALYs lost compared with patients treated with SOC. Aducanumab treatment translated to a lower lifetime probability of transitioning to AD dementia, a lower lifetime probability of transitioning to institutionalization (25.2% vs. 29.4%), delays in the median time to transition to AD dementia (7.50 vs. 4.92 years from MCI to moderate AD dementia or worse), and an incremental median time in the community of 1.32 years compared with SOC. The model predicted long-term benefits of aducanumab treatment in patients with MCI due to AD and mild AD dementia and their caregivers. The predicted outcomes provide a foundation for healthcare decision-makers and policymakers to understand the potential clinical and socioeconomic value of aducanumab.
Identifiants
pubmed: 34426940
doi: 10.1007/s40120-021-00273-0
pii: 10.1007/s40120-021-00273-0
pmc: PMC8571451
doi:
Types de publication
Journal Article
Langues
eng
Pagination
919-940Informations de copyright
© 2021. The Author(s).
Références
Alzheimer's Society UK. Facts for the media 2021. https://www.alzheimers.org.uk/about-us/news-and-media/facts-media .
World Health Organization. Dementia: number of people affected to triple in next 30 years 2017. https://www.who.int/news/item/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years . Accessed 27 July 2021.
Alzheimer's Association. 2020 Alzheimer's disease facts and figures. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12068 . Accessed 27 July 2021.
Centers for Disease Control and Prevention. Caregiving for a person with Alzheimer's disease or a related dementia. https://www.cdc.gov/aging/caregiving/alzheimer.htm . Accessed 27 July 2021.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292–323.
pubmed: 27012484
pmcid: 6417794
Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45(3):358–68.
pubmed: 10072051
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.
pubmed: 3220946
pmcid: 3220946
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
pubmed: 29653606
pmcid: 29653606
Centers for Disease Control and Prevention. CDC Wonder. Accessed [Jul 27, 2021]. https://wonder.cdc.gov/
Knopman DS, Gottesman RF, Sharrett AR, Wruck LM, Windham BG, Coker L, et al. Mild cognitive impairment and dementia prevalence: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Alzheimers Dement. 2016;2:1–11.
Lopez-Anton R, Santabarbara J, De-la-Camara C, Gracia-Garcia P, Lobo E, Marcos G, et al. Mild cognitive impairment diagnosed with the new DSM-5 criteria: prevalence and associations with non-cognitive psychopathology. Acta Psychiatr Scand. 2015;131(1):29–39.
pubmed: 24893954
Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126–35.
pubmed: 29282327
pmcid: 5772157
Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286–94.
pubmed: 30938796
pmcid: 6450276
Robinson RL, Rentz DM, Andrews JS, Zagar A, Kim Y, Bruemmer V, et al. Costs of early stage Alzheimer’s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US)1. J Alzheimers Dis. 2020;75(2):437–50.
pubmed: 32250304
pmcid: 7306889
Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, et al. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer’s disease in three European countries–study design and baseline findings. J Alzheimers Dis. 2013;36(2):385–99.
pubmed: 23629588
El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the Iceberg: assessing the global socioeconomic costs of Alzheimer’s disease and related dementias and strategic implications for stakeholders. J Alzheimers Dis. 2019;70(2):323–41.
pubmed: 31256142
pmcid: 31256142
Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, et al. Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011;7(3):318–27.
pubmed: 21575872
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15(5):455–532.
pubmed: 26987701
Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):189–202.
pubmed: 28351177
pmcid: 5494694
Gustavsson A, Pemberton-Ross P, Gomez Montero M, Hashim M, Thompson R. Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):563–70.
pubmed: 32951480
Makin C, Neumann P, Peschin S, Goldman D. Modelling the value of innovative treatments for Alzheimer’s disease in the United States. J Med Econ. 2021;24(1):764–9.
pubmed: 33989095
Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimers Dis. 2019;67(3):779–94.
pubmed: 30689575
pmcid: 6398562
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589–99.
pubmed: 7462122
pmcid: 7462122
Aduhelm (aducanumab-avwa). Prescribing information. Biogen, Inc; 2021 Accessed [July 27, 2021]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf
Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.
pubmed: 27582220
pmcid: 27582220
Budd D, Burns LC, Guo Z, L’Italien G, Lapuerta P. Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: a Markov model simulation. Clinicoecon Outcomes Res. 2011;3:189–95.
pubmed: 22046104
pmcid: 3202482
Djalalov S, Yong J, Beca J, Black S, Saposnik G, Musa Z, et al. Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. Mol Diagn Ther. 2012;16(6):389–99.
pubmed: 23188525
Skoldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease–a simulation study. Curr Alzheimer Res. 2013;10(2):207–16.
pubmed: 23036018
Wimo A, Handels R, Winblad B, Black CM, Johansson G, Salomonsson S, et al. Quantifying and describing the natural history and costs of Alzheimer’s disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75(3):891–902.
pubmed: 32390617
pmcid: 7369101
O’Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s research consortium study. Arch Neurol. 2008;65(8):1091–5.
pubmed: 18695059
pmcid: 3409562
Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force–3. Value Health. 2012;15(6):812–20.
pubmed: 22999130
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.
pubmed: 21514249
pmcid: 21514249
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.
pubmed: 21514250
pmcid: 21514250
Potashman M, Buessing M, Benea ML, Cummings J, Borson S, Pemberton-Ross P, et al., editors. Estimating progression rates across the spectrum of Alzheimer’s disease for amyloid positive individuals using National Alzheimer’s Coordinating Center data. Clinical Trials on Alzheimer's Disease Congress 2020; 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772113/ shown as J Prev Alzheimers Dis. 202;7(suppl 1):55–119. Poster 070. Accessed 27 July 2021.
Davis M, Thomas OC, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer’s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res. 2018;15(8):777–88.
pubmed: 29357799
pmcid: 6156780
Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigmine. Pharmacoeconomics. 2000;17(4):351–60.
pubmed: 10947490
Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology. 1999;52(6):1138–45.
pubmed: 10214734
Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Curr Alzheimer Res. 2012;9(9):1050–8.
pubmed: 22175655
pmcid: 3690579
Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, et al. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27–32.
pubmed: 10413389
Wilson RS, Aggarwal NT, Barnes LL, Bienias JL, Mendes de Leon CF, Evans DA. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2009;66(6):767–72.
pubmed: 19506138
pmcid: 2743243
Arias E, Xu J. United States life tables, 2017. Natl Vital Stat Rep. 2019;68(7):1–66.
pubmed: 32501200
Andersen K, Lolk A, Martinussen T, Kragh-Sorensen P. Very mild to severe dementia and mortality: a 14-year follow-up—the Odense study. Dement Geriatr Cogn Disord. 2010;29(1):61–7.
pubmed: 20110702
von Rosenstiel P, Haeberlein S, Castrillo-Viguera C, Chen T, O’Gorman J, Rajagovindan R, et al., editors. Aducanumab 48-month analyses from PRIME, a phase 1b study in patients with early Alzheimer’s disease. 11th Clinical Trials on Alzheimer’s Disease Congress 2018; 2018; Barcelona, Spain.
Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al. Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12(1):154.
pubmed: 33208190
pmcid: 7677851
Hongisto K, Vaatainen S, Martikainen J, Hallikainen I, Valimaki T, Hartikainen S, et al. Self-rated and caregiver-rated quality of life in Alzheimer disease with a focus on evolving patient ability to respond to questionnaires: 5-year prospective ALSOVA Cohort Study. Am J Geriatr Psychiatry. 2015;23(12):1280–9.
pubmed: 26560513
Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jonsson L. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res. 2010;7(4):358–67.
pubmed: 19939223
Janssen B, Szende A. Population norms for the EQ-5D. In: Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014. p. 19–30.
ICER. A guide to ICER's methods for health technology assessment. 2018. http://icer-review.org/wp-content/uploads/2018/08/ICER-HTA-Guide_082018.pdf . Accessed 27 July 2021.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
pubmed: 27623463
Green C, Handels R, Gustavsson A, Wimo A, Winblad B, Skoldunger A, et al. Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework. Alzheimers Dement. 2019;15(10):1309–21.
pubmed: 31402324
IPECAD Modelling Group. The IPECAD Open-Source Model Version 1.1. 2021 2021 [Available from: https://ipecadgroup.wordpress.com/open-source-model/ . Accessed 1 Mar 2021.
Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888–98.
pubmed: 31164314
pmcid: 31164314
Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer’s disease archimedes condition-event simulator: development and validation. Alzheimers Dement (NY). 2018;4:76–88.
Iaccarino L, Sala A, Perani D. Alzheimer’s disease neuroimaging I. Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET. Ann Clin Transl Neurol. 2019;6(6):1113–20.
pubmed: 31211176
pmcid: 6562030
Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, et al. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327–38.
pubmed: 25693589
pmcid: 5013930
US Food and Drug Administration. Expedited programs for serious conditions–drugs and biologics. 2014. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics . Accessed 27 July 2021.
Alzheimer's Association. Changing the trajectory of Alzheimer’s disease: How a treatment by 2025 saves lives and dollars 2015. https://www.alz.org/media/documents/changing-the-trajectory-r.pdf . Accessed 27 July 2021.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903.
pubmed: 22397651
Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Martins RN, et al. Amyloid beta-associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimers Dement (Amst). 2017;8:156–64.
Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, et al. Disease progression meta-analysis model in Alzheimer’s disease. Alzheimers Dement. 2010;6(1):39–53.
pubmed: 19592311
Wattmo C, Wallin AK, Minthon L. Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies. Alzheimers Res Ther. 2013;5(5):44.
pubmed: 24099236
pmcid: 3978889
Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ. 1997;315(7122):1577–82.
pubmed: 9437275
pmcid: 2127969